The facts
The randomized, open-label trial enrolled 1,298 adults with type 2 diabetes. It compared weekly retatrutide 9 mg or 12 mg with Ozempic 2 mg for 80 weeks. [1][2][3]
Lilly reported A1c reductions of 2.2 percentage points for both retatrutide doses versus 1.8 for Ozempic. Weight reductions were 19.5%, 20.9% and 9.4%, respectively. [1][2]
These figures use an efficacy estimand: estimated outcomes if participants stayed on treatment without extra glucose-lowering medication. They are not an all-participant real-world estimate. [1]
Adverse-event discontinuation rates were 4.8%, 7.9% and 2.7%, respectively. Gastrointestinal effects were common. Retatrutide remains unapproved. [1]
Still unconfirmed
- Full study publication and independent assessment of the complete dataset remain pending.
Sources
References support the numbered facts above. Source checks: 29 Oct 2026, 19:03 UTC.
The announcement and trial design were checked against Reuters and the registry. Sponsor-reported superiority is not presented as independent replication or approval.
- TRANSCEND-T2D-2 top-line results
Eli Lilly and Company · Primary source · 28 Oct 2026
Sponsor announcement; top-line efficacy-estimand results, not a peer-reviewed paper.
- Retatrutide and Ozempic trial results
Reuters via PM360 · Reporting · 28 Oct 2026
Sriparna Roy’s Reuters report. Reuters is independently owned from Lilly; the numerical results come from the sponsor.
- NCT06260722 study record
ClinicalTrials.gov · Primary source · 28 Sept 2026
NLM registry record read through its public API. The older enrollment estimate is 1,250, distinct from Lilly’s reported actual enrollment of 1,298; the registry does not independently validate the results.